Kevin E. Noonan

Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.

A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.